Manufacturer
INTAS PHARMACEUTICALS LIMITED
Contents
Pemetrexed
Indication
Malignant pleural mesothelioma: In combination w/ cisplatin for chemotherapy-naive patients w/ unresectable malignant pleural mesothelioma. Non-small cell lung cancer: Monotherapy for 2nd-line treatment or in combination w/ cisplatin as 1st-line treatment of patients w/ locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Monotherapy for maintenance of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy
Instruction
Administer via IV infusion
Drug interaction
Delayed clearance w/ nephrotoxic drugs, probenecid & penicillin. Decreased elimination & increased occurrence of adverse events w/ high-dose NSAIDs & aspirin. Monitor increased INR frequency w/ anticoagulation treatment. Fatal generalized vaccinale disease w/ yellow fever vaccine. Increased systemic, possibly fatal, disease w/ live attenuated vaccines.
Malaysia
